Spin-Off

In a major strategic shift, Old Republic has spun off its TPA division into Lodestar, a new independent brand aiming for growth in a competitive market.

David Bahnsen’s top Forbes ranking coincides with his firm's 11th anniversary, validating a high-growth journey from a Morgan Stanley spin-off to a powerhouse.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

With its public debut on the horizon, S&P Global Mobility hires a seasoned expert in corporate separations to lead its financial structuring.

Emerging player LunR Royalties finalizes a transformational silver stream on the Fruta Del Norte mine, a move poised to reshape its future and reward Lundin Gold's investors.

After 40 years as a silent partner to global brands, Intercon Chemical is launching its own high-stakes medical cleaning lines to meet new safety standards.

Kanazawa's Hyakumangoku Festival blends samurai legacy with TV fame and a powerful gesture of solidarity for the Noto region's earthquake recovery.

Fancamp Exploration is splitting into two companies, creating a stable royalty firm and a high-stakes gold explorer, Goldera, to unlock shareholder value.

Allspring's closed-end funds offer tempting yields, but tiny shifts in their monthly payouts reveal a complex story of risk, return, and capital erosion.

Lysander Funds plans to convert its Canso Credit Income Fund to an ETF, tapping into a booming active fund market and seeking greater liquidity for investors.

As GLP-1 drug demand soars, Nordic Cold Chain Solutions launches a new lab to solve the complex puzzle of keeping these sensitive medicines safe.

Riding high on record 2025 results and a new FDA approval, LivaNova faces intense scrutiny ahead of its May 6 earnings call. Can it sustain the momentum?

For 45 years, one program has quietly built global bridges in American living rooms. This is the story of how human connection defies global division.

Capstone Holding Corp. merges Midwest operations, targeting positive EBITDA by 2026 amid major project wins and a disciplined cost-cutting campaign.

A groundbreaking study proves a botanical compound enhances protein absorption, leading to measurable gains in muscle strength and mass, especially for older adults.

A new platform is launching to connect pharma companies directly with 70+ global regulators, promising to slash approval times and speed patient access.

The homesite developer declared a $0.76 quarterly dividend, showcasing a resilient model that thrives by offering builders an asset-light land strategy.

Endevica Bio launches Kalohexis, a new biotech aiming to disrupt the obesity market with a drug that resets the body's 'metabolic thermostat'.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

Ultralytics, creator of the popular YOLO models, launches a new platform to streamline the chaotic world of computer vision development from start to finish.